RNA vs. FOLD, MOR, TGTX, MRVI, ARWR, CORT, MRUS, BHC, MLTX, and JANX
Should you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Amicus Therapeutics (FOLD), MorphoSys (MOR), TG Therapeutics (TGTX), Maravai LifeSciences (MRVI), Arrowhead Pharmaceuticals (ARWR), Corcept Therapeutics (CORT), Merus (MRUS), Bausch Health Companies (BHC), MoonLake Immunotherapeutics (MLTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Amicus Therapeutics (NASDAQ:FOLD) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.
In the previous week, Amicus Therapeutics and Amicus Therapeutics both had 13 articles in the media. Amicus Therapeutics' average media sentiment score of 0.48 beat Avidity Biosciences' score of 0.46 indicating that Avidity Biosciences is being referred to more favorably in the news media.
Amicus Therapeutics has higher revenue and earnings than Avidity Biosciences. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
Amicus Therapeutics has a net margin of -34.73% compared to Amicus Therapeutics' net margin of -2,103.78%. Amicus Therapeutics' return on equity of -37.98% beat Avidity Biosciences' return on equity.
Amicus Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
Amicus Therapeutics currently has a consensus target price of $17.50, suggesting a potential upside of 82.86%. Avidity Biosciences has a consensus target price of $38.29, suggesting a potential upside of 29.78%. Given Avidity Biosciences' higher possible upside, research analysts plainly believe Amicus Therapeutics is more favorable than Avidity Biosciences.
Amicus Therapeutics received 379 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 73.50% of users gave Amicus Therapeutics an outperform vote while only 64.62% of users gave Avidity Biosciences an outperform vote.
Summary
Amicus Therapeutics beats Avidity Biosciences on 9 of the 15 factors compared between the two stocks.
Get Avidity Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avidity Biosciences Competitors List
Related Companies and Tools
